Monitor early U.S. commercial uptake of MYQORZO and topline results from the ACACIA-HCM trial in Q2 2026, which could validate expansion into non-obstructive HCM. The high cash balance supports operations, but the significant increase in operating expenses raises questions about profitability timeline.
Price Chart
Executive Summary
Cytokinetics reported its transition to a commercial-stage company following FDA, China, and EU approvals of MYQORZO for obstructive HCM, with the U.S. launch underway. The company posted a wider net loss of $785M in 2025 due to increased R&D and commercial readiness spending, while maintaining ~$1.22B in cash. It provided 2026 guidance with $830M–$870M in combined R&D and SG&A expenses.
Key Financial Metrics
Key Facts
- MYQORZO approved in U.S., China, and EU for symptomatic obstructive HCM; U.S. launch began in January 2026 with first prescriptions dispensed.
- Total 2025 revenue was $88.0M (up from $18.5M in 2024), driven by a $52.4M technology transfer payment to Bayer and $15.0M in milestone revenue from MYQORZO approvals.
- 2025 net loss was $785.0M (vs. $589.5M in 2024); Q4 2025 net loss was $183.0M (vs. $150.0M in Q4 2024), reflecting higher R&D and G&A expenses for commercialization.
- Cash, cash equivalents, and investments were $1.22B as of December 31, 2025, down from $1.25B in Q3; excluding a $100M loan draw, cash declined by $134M in Q4.
- 2026 guidance: GAAP combined R&D and SG&A expenses of $830M–$870M, including $120M–$130M in non-cash stock-based compensation.
Financial Impact
Revenue increased 376% YoY to $88.0M in 2025, but net loss widened by $195.5M due to $76.6M higher R&D and $69.0M higher G&A expenses. Cash burn (excluding financing) was $134M in Q4 2025.
Segment Breakdown
| Segment | Revenue |
|---|---|
| aficamten | $15.0M |
| technology transfer | $52.4M |
Risk Factors
- High cash burn rate ($134M in Q4 excluding financing) could pressure the balance sheet if product revenue does not scale quickly.
- Future profitability depends on MYQORZO's commercial success and additional regulatory approvals, which are not guaranteed.
- Increased G&A spend ($284.3M in 2025) reflects sales force buildout, creating fixed costs that require strong revenue growth to offset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-067012 |
| Document: cytk-20260224.htm | 0001193125-26-067012 |
| Document: 0001193125-26-067012-index-headers.html | 0001193125-26-067012 |
| Document: 0001193125-26-067012-index.html | 0001193125-26-067012 |
| Document: 0001193125-26-067012.txt | 0001193125-26-067012 |
| CONTEXT: Previous Earnings (2026-02-24) | 0001193125-26-067012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.26 (+5.84%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.26 (−9.92%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.26 (−8.59%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.26 (−8.59%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.26 (−7.96%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.26 (−9.47%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.26 (−18.84%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.26 (−19.05%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.26 (−19.17%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.26 (−20.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access